Document Detail


Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC.
MedLine Citation:
PMID:  23023514     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Collapsin response mediator protein-2 (CRMP-2) is the first described and most studied member of a family of proteins that mediate the addition of tubulin dimers to the growing microtubule. CRMPs have mainly been studied in the nervous system, but recently, they have been described in other tissues where they participate in vesicle transport, migration and mitosis. In this work, we aimed at studying the role of CRMP-2 in lung cancer cell division. We first explored the expression of CRMP-2 and phosphorylated (Thr 514) CRMP-2 in 91 samples obtained from patients with localized non-small cell lung cancer. We observed a significant correlation between high levels of nuclear phosphorylated CRMP-2 and poor prognosis in those patients. Interestingly, this association was only positive for untreated patients. In order to provide a mechanistic explanation to these findings, we used in vitro models to analyze the role of CRMP-2 and its phosphorylated forms in cell division. Thus, we observed by confocal microscopy and immunoprecipitation assays that CRMP-2 differentially co-localizes with the mitotic spindle during cell division. The use of phosphodefective or phosphomimetic mutants of CRMP-2 allowed us to prove that anomalies in the phosphorylation status of CRMP-2 result in changes in the mitotic tempo, and increments in the number of multinucleated cells. Finally, here we demonstrate that CRMP-2 phosphorylation impairment, or silencing induces p53 expression and promotes apoptosis through caspase 3 activation. These results pointed to CRMP-2 phosphorylation as a prognostic marker and potential new target to be explored in cancer therapy. © 2012 Wiley-Liss, Inc.
Authors:
Erik Oliemuller; Rafael Peláez; Saray Garasa; María J Pajares; Jackeline Agorreta; Rubén Pío; Luis M Montuenga; Alvaro Teijeira; Susana Llanos; Ana Rouzaut
Related Documents :
15231994 - A family of acrp30/adiponectin structural and functional paralogs.
24646054 - Afatinib for the treatment of advanced non-small-cell lung cancer.
8708554 - Gh inhibition of lipogenesis and stimulation of lipolysis in sheep adipose tissue: invo...
19561084 - Raptor binds the sain (shc and irs-1 npxy binding) domain of insulin receptor substrate...
24106124 - Rapamycin inhibits the production of myofibroblasts and reduces corneal scarring after ...
13130514 - Protective effects of sesamin and sesamolin on hypoxic neuronal and pc12 cells.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-1
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  -     ISSN:  1097-0215     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-1     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 UICC.
Affiliation:
Oncology Division, Center for Applied Medical Research (CIMA). University of Navarra. Pío XII, 55 Pamplona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Letter to the Editor on NaV1.8.
Next Document:  A facile and general preparation of high-performance noble-metal-based free-standing nanomembranes b...